RVMD
Revolution MedicinesBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
The bull case remains that the RASolute 302 survival data materially advanced daraxonrasib toward a filing path and that the May 6 Q1 update kept the clinical and funding story intact, with roughly $2.1 billion of April net proceeds added after the Q1 balance-sheet date. [#10-Q-2026-05-06]
Posture
Constructive
Lead driver
Momentum
What changed
5 setup hits (3d) with net bullish as of 2026-06-03.
What can break
Clinical success still has to convert into an NDA and approval; the 10-Q notes FDA/CNPV timing and acceptance are not assured even if the company intends to use RASolute 302 in a future filing. [#10-Q-2026-05-06]
Momentum
94
Value
41
Sentiment
36
Setup hits (3d)
5 · Net Bullish
AI TargetsBase $132.00 · Bull $165.00 · Bear $105.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $132.32
Why
Momentum94 · Δ7d -1.2
Value41 · Δ7d +0.1
Sentiment36 · Δ7d -3.9
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
94
34% active weight
Current posture
7d trendSoftening
Δ7d
-1.2
Δ21d
-4.1
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
36
33% active weight
Current posture
7d trendSoftening
Δ7d
-3.9
Δ21d
-4.1
Why this grade
Composite grade B. Momentum 93.6 / Value 41.1 / Sentiment 36.1
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$32.17B
Beta
1.00
Shares Out
193.32M
P/E (TTM) · Derived
-28.0
P/S (TTM)
-
P/FCF (TTM) · Derived
-39.62
Rev YoY
-100.0%
EPS YoY
-72.2%
Gross Margin
-
Op Margin
-88409.3%
Net Debt
-$2.29B
Current Ratio
8.05
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology